The Democratic Republic of Congo is set to receive 70,000 doses of the Ervebo vaccine from the global Ebola stockpile, the World Health Organization announced this week, as the country battles what has become the deadliest Ebola outbreak in its history.
The allocation, approved by the International Coordinating Group on Vaccine Provision following a request from the Congolese government, comes at a critical moment in the fight against the disease. Of the 70,000 doses, 50,000 will be allocated directly to frontline responders and health workers who are most at risk of exposure. At the same time, the virus, while the remaining 20,000 doses will be used in a Phase 3 clinical trial designed to determine the vaccine’s effectiveness against the Bundibugyo strain of Ebola currently driving the outbreak.
Health officials say the current outbreak has now surpassed the toll of the devastating 2018-2020 Ebola epidemic, making it the worst the country has ever recorded. According to the latest situation update from the Congolese Ministry of Health, confirmed Ebola infections have climbed to 5,208, with 2,476 deaths linked to the outbreak. That puts the case fatality rate at roughly 47.5 percent, a grim figure that underscores the severity of this particular Ebola strain and the urgency behind the vaccine rollout.
The Ebola outbreak has spread across 56 health zones in six provinces, including Haut-Uele, Ituri, North Kivu, South Kivu, Bas-Uele and Tshopo, stretching the country’s already fragile health infrastructure. Roughly 730 patients remain in isolation or under hospital care, while about 1,115 people have recovered from the disease so far, offering a measure of hope even as case numbers continue to climb in several regions.
Ervebo, the vaccine being deployed, is already licensed and widely recommended for outbreaks caused by the Zaire strain of Ebola virus disease. However, the current outbreak is being driven by the Bundibugyo virus, a related but distinct strain for which no vaccine or specific treatment has yet been formally approved. Early laboratory and animal studies suggest Ervebo may offer some cross-protection against Bundibugyo, but health authorities say the clinical trial now underway is essential to confirm whether that protection holds up in humans.
WHO Director-General Tedros Adhanom Ghebreyesus described the vaccine allocation as an important example of global solidarity in action. He said the organization, together with national authorities and international partners, remains committed to strengthening surveillance, improving rapid detection, deepening community engagement and expanding vaccination efforts to bring the Ebola outbreak under control.
Earlier this week, the WHO reiterated that the Ebola outbreak in the Democratic Republic of Congo continues to constitute a public health emergency of international concern, a designation that mobilizes additional global resources and coordination to contain the disease’s spread. The classification also reflects growing concern that without swift intervention, the outbreak could spread further across borders in an already volatile region.
Public health experts note that vaccine access remains one of the most powerful tools available in curbing Ebola transmission, particularly among health workers who face the highest risk of exposure while treating patients. By prioritizing frontline responders in this latest shipment, authorities hope to protect the very people whose work is central to containing the outbreak, while simultaneously gathering the clinical data needed to expand protection more broadly.
As the Ervebo doses make their way to affected provinces, health officials and aid organizations are urging continued vigilance, noting that community trust, rapid case detection and consistent vaccine supply will all be critical in determining how quickly this historic Ebola outbreak can finally be brought to an end.
